Skip to main content
Log in

Better Analysis for Better Decisions

Facing Up to the Challenges

  • Editorial
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24 (11): 1043–1053

    Article  PubMed  Google Scholar 

  2. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006; 24 (11): 1055–1068

    Article  PubMed  Google Scholar 

  3. Torrance GW. Utility measurement in healthcare: the things I never got to. Pharmacoeconomics 2006; 24 (11): 1069–1078

    Article  PubMed  Google Scholar 

  4. Briggs AH, Levy AR. Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven? Pharmacoeconomics 2006; 24 (11): 1079–1086

    Article  PubMed  Google Scholar 

  5. Sculpher MJ, Drummond MF. Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics 2006; 24 (11): 1087–1099

    Article  PubMed  Google Scholar 

  6. Manca A, Willan AR. ‘Lost in translation’: accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics 2006; 24 (11): 1101–1119

    Article  PubMed  Google Scholar 

  7. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006; 24 (11): 1121–1131

    Article  PubMed  Google Scholar 

  8. Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics 2006; 24 (11): 1133–1143

    Article  PubMed  Google Scholar 

  9. Goeree R, Levin L. Building bridges between academic research and policy formulation: the PRUFE framework — an integral part of Ontario’s evidence-based HTPA process. Pharmacoeconomics 2006; 24 (11): 1145–1158

    Article  Google Scholar 

  10. Laupacis A. Economic evaluations in the Canadian common drug review. Pharmacoeconomics 2006; 24 (11): 1159–1164

    Article  Google Scholar 

  11. Neumann PJ, Sullivan SD. Economic evaluation in the US: what is the missing link? Pharmacoeconomics 2006; 24 (11): 1165–1170

    Article  Google Scholar 

  12. Briggs A, Buxton M, Drummond MF, et al. Unfinished sympathy: a tribute to the life and career of Bernie O’Brien (1959–2004). Med Decis Making 2004; 24 (5): 538–544

    Article  PubMed  Google Scholar 

  13. Gold M, Seigel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996

    Google Scholar 

  14. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NIC, 2004

    Google Scholar 

Download references

Acknowledgements

We are grateful to all the speakers at the Conference, who so generously gave of their time. We are also grateful to Greg Stoddart and the other members of the Conference Organising Committee, without whose help and support this event would not have been possible.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael F. Drummond.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drummond, M.F., Sculpher, M.J. Better Analysis for Better Decisions. Pharmacoeconomics 24, 1039–1042 (2006). https://doi.org/10.2165/00019053-200624110-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200624110-00001

Navigation